Daily sunscreen application increased in participants of a study over a six-week period, according to a report in the November issue of the Archives of Dermatology.

Two new studies suggest that skin cancer can be inhereited.

Skin cancer has always been attributed to exposure to the sun. In particular, those who receive bad sunburns when young, particularly as a baby, have a higher incidence of skin cancer. However, new studies are pointing to a genetic predisposition to skin cancer as well.

Patients with soft-tissue sarcomas at high risk of spreading were 30% more likely to be alive and cancer free almost three years after starting treatment if their tumours were heated at the time they received chemotherapy, according to new research. The finding bolsters the case for intensifying exploration of the strategy in other types of cancer.

Scientists have uncovered a new role played by Vitamin C in protecting the skin.

Tiny, solitary spikes that stick out of nearly every cell in the body play a central role in a type of skin cancer, new research has found. The discovery in mice shows that the microscopic structures known as primary cilia can either suppress or promote this skin cancer, depending on the mutation triggering the disease.

A virus discovered last year in a rare form of skin cancer has also been found in people with the second most common form of skin cancer among Americans, according to researchers at the Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute.

This likely falls under the category of "common sense." The World Health Organization's International Agency for Research on Cancer (IARC) announced on Tuesday that it has moved UV tanning beds to its highest cancer risk category: "carcinogenic to humans."

Scientists from the Queensland Institute of Medical Research (QIMR) have found two new genes that together double a person's risk of developing melanoma.

Aldara is one of the trade names of Imiquimod (INN), a prescription medication that acts as an immune response modifier. It is marketed by MEDA AB, Graceway Pharmaceuticals and iNova Pharmaceuticals under the trade name Aldara and by Mochida as Beselna.